Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

BRAD S KAHL

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1407822430
CMS profile
1114950
Location
SAINT LOUIS, MO

General Payments · PY2018–2024

$343,211.09

  • Reported across 257 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$51,960.08

33 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
ADC Therapeutics America, Inc. $10,444.62 8
Acerta Pharma LLC $6,165.00 2
PFIZER INC. $5,220.00 1
Genentech USA, Inc. $5,130.00 2
E.R. Squibb & Sons, L.L.C. $3,460.00 2
GlaxoSmithKline, LLC. $3,300.00 1
F. Hoffmann-La Roche AG $3,273.50 4
ABBVIE INC. $3,218.82 5
Merck Sharp & Dohme Corporation $3,050.00 1
BeiGene USA, Inc. $2,937.50 2
Eli Lilly and Company $2,475.00 1
AstraZeneca UK Limited $1,370.00 1
Acrotech Biopharma Inc. $1,350.00 1
Genentech, Inc. $550.00 1
Gilead Sciences, Inc. $15.64 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $38,596.72 37
PY2019 $71,936.49 66
PY2020 $46,822.10 30
PY2021 $36,762.50 20
PY2022 $49,319.48 29
PY2023 $47,813.72 42
PY2024 $51,960.08 33

Payment records · PY2024 (33)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
ABBVIE INC. $1,375.00 01/23/2024 Consulting Fee Undisputed 01/23/2026 1103135773 CMS
ABBVIE INC. $550.00 01/24/2024 Consulting Fee Undisputed 01/23/2026 1103135775 CMS
ABBVIE INC. $550.00 04/04/2024 Consulting Fee Undisputed 01/23/2026 1103135777 CMS
ABBVIE INC. $725.00 07/19/2024 Consulting Fee Undisputed 01/23/2026 1103135779 CMS
ABBVIE INC. $18.82 09/11/2024 Food and Beverage Undisputed 01/23/2026 1104019073 CMS
Acrotech Biopharma Inc. $1,350.00 01/29/2024 Consulting Fee Undisputed 01/23/2026 1147105297 CMS
ADC Therapeutics America, Inc. $660.20 03/01/2024 Travel and Lodging Undisputed 01/23/2026 1121187678 CMS
ADC Therapeutics America, Inc. $299.79 03/01/2024 Travel and Lodging Undisputed 01/23/2026 1121187680 CMS
ADC Therapeutics America, Inc. $100.97 03/01/2024 Food and Beverage Undisputed 01/23/2026 1121187682 CMS
ADC Therapeutics America, Inc. $62.50 03/01/2024 Food and Beverage Undisputed 01/23/2026 1121187684 CMS
ADC Therapeutics America, Inc. $52.17 03/01/2024 Food and Beverage Undisputed 01/23/2026 1121187686 CMS
ADC Therapeutics America, Inc. $43.99 03/01/2024 Food and Beverage Undisputed 01/23/2026 1121187688 CMS
ADC Therapeutics America, Inc. $25.00 03/01/2024 Food and Beverage Undisputed 01/23/2026 1121187690 CMS
ADC Therapeutics America, Inc. $9,200.00 04/26/2024 Consulting Fee Undisputed 01/23/2026 1121187676 CMS
AstraZeneca Pharmaceuticals LP $4,110.00 08/01/2024 Consulting Fee Undisputed 01/23/2026 1105420132 CMS
AstraZeneca Pharmaceuticals LP $2,055.00 09/24/2024 Consulting Fee Undisputed 01/23/2026 1104569794 CMS
AstraZeneca UK Limited $1,370.00 10/15/2024 Consulting Fee Undisputed 01/23/2026 1094041101 CMS
BeiGene USA, Inc. $1,100.00 01/12/2024 Consulting Fee Undisputed 01/23/2026 1120845054 CMS
BeiGene USA, Inc. $1,837.50 06/28/2024 Consulting Fee Undisputed 01/23/2026 1120845049 CMS
E.R. Squibb & Sons, L.L.C. $2,076.00 01/11/2024 Consulting Fee Undisputed 01/23/2026 1101244984 CMS
E.R. Squibb & Sons, L.L.C. $1,384.00 04/02/2024 Consulting Fee Undisputed 01/23/2026 1101244992 CMS
Eli Lilly and Company $2,475.00 02/23/2024 Consulting Fee Undisputed 01/23/2026 1136074637 CMS
F. Hoffmann-La Roche AG $687.50 03/08/2024 Consulting Fee Undisputed 01/23/2026 1132981967 CMS
F. Hoffmann-La Roche AG $1,470.00 10/10/2024 Consulting Fee Undisputed 01/23/2026 1132981969 CMS
F. Hoffmann-La Roche AG $1,100.00 12/06/2024 Consulting Fee Undisputed 01/23/2026 1132981971 CMS
F. Hoffmann-La Roche AG $16.00 12/06/2024 Food and Beverage Undisputed 01/23/2026 1132981973 CMS
Genentech USA, Inc. $2,850.00 06/05/2024 Consulting Fee Undisputed 01/23/2026 1132981963 CMS
Genentech USA, Inc. $2,280.00 11/11/2024 Consulting Fee Undisputed 01/23/2026 1132981965 CMS
Genentech, Inc. $550.00 04/08/2024 Consulting Fee Undisputed 01/23/2026 1132981975 CMS
Gilead Sciences, Inc. $15.64 12/16/2024 Food and Beverage Undisputed 01/23/2026 1133832109 CMS
GlaxoSmithKline, LLC. $3,300.00 02/19/2024 Consulting Fee Undisputed 01/23/2026 1116719350 CMS
Merck Sharp & Dohme LLC $3,050.00 11/18/2024 Consulting Fee Undisputed 01/23/2026 1141667226 CMS
PFIZER INC. $5,220.00 08/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1131373919 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.